SPECIATION OF IODINE IN SOIL SOLUTION IN FOREST AND GRASSLAND SOILS IN ROKKASHO, JAPAN.

The behaviour of I in soil depends on its chemical form in soil solution. Stable I (127I) in the soil solution under actual soil conditions was investigated as a natural analogue of long-lived radioiodine (129I). Soil samples were collected at 5-cm depth intervals down to 20 cm from forests and grasslands in Rokkasho, where the Japanese first commercial nuclear fuel reprocessing plant is located, and the soil solution was extracted by centrifugation. Almost half of total I in the soil solution was iodide, and the other half was dissolved organic I (DOI), with iodate under the detection limit. The proportion of DOI in total I at 0-5 cm depth was larger than the proportions at 5-20 cm depth. The concentration of DOI was positively correlated with that of DOC in the soil solution, suggesting that the behaviour of DOI in the surface soil is affected by labile organic matter dynamics.

A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy.

PURPOSE: To compare seed loss and dosimetric parameters between stranded and loose 125I seeds (LS) for prostate brachytherapy. METHODS AND MATERIALS: Sixty-four patients with 1997 American Joint Commission on Cancer (AJCC) clinical stage T1c or T2a prostate carcinoma were prospectively randomized to brachytherapy (144Gy) with RAPID Strand 125I seeds (RS) vs. LS (Oncura, Plymouth Meeting, PA) The treatment plan for each patient was devised before randomization, and was not modified based on the randomization. Each patient underwent magnetic resonance, computed tomography, and plain film radiographs on the day of the implant (Day 0) and 30 days later (Day 30). RESULTS: Overall, 21 of 62 patients (30%) experienced seed loss. Seed loss occurred in 15 of 32 of LS patients (47%) vs. 6 of 30 RS patients (23%; p=0.053). Mean seed loss was 1.09 in the LS patient vs. 0.43 in RS patients (p=0.062). Eight LS patients (25%) lost multiple seeds, compared to 3 stranded patients (10%). Despite the lesser degree of seed loss in patients who received stranded seeds, they had a paradoxical trend toward lower V100 and D90 values. CONCLUSION: This prospective randomized trial showed a strong trend toward a decrease in postimplant seed loss with stranded seeds. Improved seed retention may be more advantageous in a setting of less generous periprostatic coverage. The lowered risk seed migration seen with stranded seeds would presumably also decrease the likelihood of lung or cardiac seed embolization.

Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131).

I-131 is a frequently used isotope for radionuclide therapy. This technique for cancer treatment requires a pre-therapeutic dosimetric study. The latter is usually performed (for this radionuclide) by directly imaging the uptake of the therapeutic radionuclide in the body or by replacing it by one of its isotopes, which are more suitable for imaging. This study aimed to compare the image quality that can be achieved by three iodine isotopes: I-131 and I-123 for single-photon emission computed tomography imaging, and I-124 for positron emission tomography imaging. The imaging characteristics of each isotope were investigated by simulated data. Their spectrums, point-spread functions, and contrast-recovery curves were drawn and compared. I-131 was imaged with a high-energy all-purpose (HEAP) collimator, whereas two collimators were compared for I-123: low-energy high-resolution (LEHR) and medium energy (ME). No mechanical collimation was used for I-124. The influence of small high-energy peaks (>0.1%) on the main energy window contamination were evaluated. Furthermore, the effect of a scattering medium was investigated and the triple energy window (TEW) correction was used for spectral-based scatter correction. Results showed that I-123 gave the best results with a LEHR collimator when the scatter correction was applied. Without correction, the ME collimator reduced the effects of high-energy contamination. I-131 offered the worst results. This can be explained by the large amount of septal penetration from the photopeak and by the collimator, which gave a low spatial resolution. I-124 gave the best imaging properties owing to its electronic collimation (high sensitivity) and a short coincidence time window.

Uncertainties in committed equivalent doses to the thyroid after ingestion or inhalation of different chemical forms of 125-129-131I.

The aim of this study is to reanalyse uncertainties in committed equivalent doses to the thyroid after ingestion of 125-129-131I using the last variability reported for anatomical and physiological parameters of the different ICRP age groups, and to estimate uncertainties after inhalation exposure to different chemical forms of iodine (elemental and organic iodine vapours, iodine loaded particles (study limited to workers for activity median aerodynamic diameters of 1 and 5 microm)). The 95% confidence interval appears in the range of 7-18 (ratio of 97.5 versus 2.5 percentile values of the log-normal distribution: GSD4). The largest uncertainties are observed for 129I which is due to its long half-life. Because of the small range of beta rays of 125-129I when compared with that of 131I, and the preferential location of iodine within the colloid of the thyroid follicles, the use of calculated doses for a realistic risk assessment is discussed.

Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy.

For targeted radionuclide therapy, the level of activity to be administered is often determined from whole-body dosimetry performed on a pre-therapy tracer study. The largest potential source of error in this method is due to inconsistent or inaccurate activity retention measurements. The main aim of this study was to develop a simple method to quantify the uncertainty in the absorbed dose due to these inaccuracies. A secondary aim was to assess the effect of error propagation from the results of the tracer study to predictive absorbed dose estimates for the therapy as a result of using different radionuclides for each. Standard error analysis was applied to the MIRD schema for absorbed dose calculations. An equation was derived to describe the uncertainty in the absorbed dose estimate due solely to random errors in activity-time data, requiring only these data as input. Two illustrative examples are given. It is also shown that any errors present in the dosimetry calculations following the tracer study will propagate to errors in predictions made for the therapy study according to the ratio of the respective effective half-lives. If the therapy isotope has a much longer physical half-life than the tracer isotope (as is the case, for example, when using 123I as a tracer for 131I therapy) the propagation of errors can be significant. The equations derived provide a simple means to estimate two potentially large sources of error in whole-body absorbed dose calculations.

Uncertainties on the committed equivalent dose to the thyroid as a function of age for different iodine isotopes.

This study compares uncertainties of equivalent doses after internal contamination by 125I, 129I or 131I. Uncertainties were calculated using reported distributions of physiological parameters and Monte Carlo simulation. In adults, uncertainties increase from 131I to 125I and 129I with 1% of the population receiving 3.9, 4.0 and 7.2 times the median dose for the respective isotopes. In newborns, these values were 7.5, 12.3 and 19.0 for 131I, 125I and 129I respectively. The ratio of the beta dose delivered to the epithelium versus a homogeneous distributed dose was estimated for different iodine concentrations in colloid, epithelium and interstitium. In adults, for 131I, about 40% of the beta dose was delivered to the epithelial cells, whereas this fraction varied depending on the concentration for 125I and 129I, i.e. 20-30% at a relative epithelial concentration of 20% and 7-14% at a concentration of 3%. Small variations were observed depending on age.

[Prevention of contrast-induced nephropathy in the context of evidence-based medicine].

The paper considers the mechanisms of development of contrast-induced nephropathy in the use of iodinated radiopaque contrast agents (RCAs), as well as the criteria of their assessment. It gives different existing recommendations for prevention of the nephrotoxic effects of RCAs.